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Abstract  
In order to broaden the knowledge on the mechanisms of development of malignant pleural 
mesothelioma (MPM), a review of works on MPM-transcriptome was performed previously and 119 
deregulated genes were identified. However, a poor consistency amongst studies was observed. Thus, 
the expression of these genes was further investigated in the present work using quantitative Real-Time 
PCR in 15 MPM and 20 non-MPM tissues. Fifty-nine genes showed a statistically significant 
deregulation and were further evaluated in two epithelioid MPM cell lines (compared to MET-5A, a 
non-MPM cell line). Nine genes (ACSL1, CCNO, CFB, PDGFRB, SULF1, TACC1, THBS2, TIMP3, 
XPOT) were deregulated with statistical significance in both the cell lines, 12 ( ASS1, CCNB1, , 
CDH11,  COL1A1, CXADR,  EIF4G1, GALNT7,  ITGA4, KRT5,      PTGIS, RAN, SOD1,  ) in at least 
one cell line, whereas seven (DSP, HEG1, MCM4, MSLN, NME2, NMU, TNPO2) were close to the 
statistical significance. Patients whose MPM tissues expressed elevated mRNA levels of BIRC5, DSP, 
NME2, and THBS2 showed a statistically significant shorter overall survival. Although MPM is a 
poorly studied cancer, some features are starting to emerge. Novel cancer genes are suggested here, in 
particular those involved in cell-cell and cell-matrix interactions.  
Key words: mesothelioma; gene expression; cancer genes; biomarkers; therapeutic targets. 
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1. Introduction 
Malignant pleural mesothelioma (MPM) is a cancer of the pleural cavity with a long latency (>20 
years) between the triggering event (i.e. exposure to asbestos) and diagnosis. Still nowadays, patients 
with MPM have poor prognosis, with overall survival (OS) typically ranging between 6 and 13 months. 
Understanding the mechanisms involved in the carcinogenesis of MPM is essential to detect clinically 
useful biomarkers and therapeutic targets. Since 1987, for CEA (carcino-embrionic antigen), and SP1 
(pregnancy specific antigen) [1], till nowadays for PPL, UPK3B, and TFPI [2], a number of alterations 
have been suggested as relevant for MPM. However, to date, the aberrant expression of EGFR [3], 
calretinin (CALB2) [4], mesothelin (MSLN) [5], MKI67 [6], MTOR [7], CD146 (MCAM) [8], MUC1 
[9], PDGFRB [10], survivin (BIRC5) [11], and the presence of mutations within NF2, CDKN2A, 
CDKN2B [12], and BAP1 [13] are the sole findings reported in a convincingly high number of 
independent studies. Thus, in order to broaden the knowledge on the mechanisms of MPM 
development, a data mining combined with a literature review of transcriptomic studies (now on 
defined as RTS) was recently performed by our own research group [14]. Nine hundred thirty one 
genes were reported as deregulated in at least one publication, but, again, only 119 were found 
deregulated by at least two independent research groups. In summary, the poor consistency among 
studies prevented to formulate solid conclusions. For this reason, in the present work the expression 
status of the 119 putatively deregulated genes was investigated and compared between MPM and non-
malignant mesothelial (NMM) tissues. Then, genes deregulated in a statistically significant way in 
tissues were further investigated in two MPM cell lines, assuming that genes differentially expressed 
both in tissues and cell lines may play a more relevant role for the disease. As a result, a series of novel 
genes putatively involved in MPM initiation, clonal evolution, or progression, is presented here in an 
attempt to contribute to the understanding of molecular mechanisms of mesothelial carcinogenesis.  
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2. Materials and methods 
 
2.1 Tissue collection 
Consecutive series of NMM and MPM specimens were collected in collaboration with the units of  
Thoracic Surgery (Department of Surgical Pathology, Medicine, Molecular, and Critical Area) and of 
the Occupational Medicine (Department of Translational Research and New Technologies in Medicine 
and Surgery), at the University Hospital of Pisa (Italy). Control tissues (20) were normal pleura from 
patients who underwent surgery for early-stage lung cancer (6 lung adenocarcinomas and 14 lung 
squamous cell carcinomas). Pleural specimens were collected far from the tumor site and eye-inspected 
by surgeons and analyzed by pathologists, in order to collect a small portion of pleura not containing 
evidence of lung cancer spread. MPM biopsies were collected at thoracoscopy before any treatment. 
About 73% of MPM patients had an ascertained positive history of exposure to asbestos and 
approximately half of them had also a positive cigarette smoking history. The complete list of 
volunteers is reported in Table 1. All samples were stored in RNA later (Qiagen, S.p.A, Milano, Italy) 
and placed at -80˚C right after the collection. They were not analysed until a clinical report with a 
precise diagnosis was issued from the pathologists, following the standard clinical routine that was 
based on microscopical inspection and immunohistochemical analyses of slides with antibodies to 
detect a panel of biomarkers (CK5/6, calretinin, vimentin, CK-Pan, EMA, TTF1, BerEP4, CEA). In 
order to focus on a specific histotype, 15 epithelioid MPM were selected and retrieved for RNA 
extraction and further analyses. According to the Helsinki declaration, volunteers gave informed 
consent for the research. The local ethical committee approved the study. 
 
2.2 Cell cultures 
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A mesothelial non-MPM cell line (MeT-5A) and two epithelioid MPM cell lines (Mero-14 and Mero-
25) were used. MeT-5A cells were purchased from the ATCC (American Type Culture Collection) 
whereas Mero-14 and Mero-25 MPM cells have been kindly donated by the University Hospital San 
Martino, Genova, Italy. MeT-5A, Mero-14, and Mero-25 cells were verified for their identity, by 
analysing the genetic markers reported in the certification. The MeT-5A cell line was grown in 
Medium199 with HEPES (Life Technologies, Monza, Italy) supplemented with 10% fetal bovine 
serum (Sigma Aldrich Corp. St Louis, MO, USA), and 1% Pen-Strep (Lonza, Basel, Switzerland), 3.3 
nM epidermal growth factor (EGF, Life Technologies, Monza, Italy), 400 nM hydrocortisone (Sigma 
Aldrich Corp. St Louis, MO, USA), and 870 nM insulin (Life Technologies, Monza, Italy). MPM cells 
were cultured in DMEM medium (Lonza, Basel, Switzerland), supplemented with 10% fetal bovine 
serum and 1% Pen-Strep. Cells were incubated at 37°C in a 5% CO2–humidified atmosphere.  
 
2.3 RNA isolation and cDNA synthesis 
Total RNA was isolated from individual samples by using Tri-Reagent (Sigma Aldrich Corp. St Louis, 
MO, USA) according to standard protocols. In order to remove possible contaminating genomic DNA, 
the extracted RNA was treated with DNase buffer (Sigma Aldrich Corp. St Louis, MO, USA). 
Concentration of clean-up RNA was determined by a spectrophotometer (SmartSpec 3000, Bio-Rad 
Laboratories, Hercules, CA). The integrity and purity of total RNA was further verified by 
electrophoresis on ethidium bromide agarose gel, inspecting the 18 and 28S ribosomal RNA bands. The 
reverse transcription (RT) was performed using the iSCRIPT cDNA Synthesis Kit departing from 1µg 
of total RNA, on a final volume of 20µl (Bio-Rad Laboratories, Hercules, CA). 
 
2.4 Selection of reference genes for quantitative Real-Time PCR (RT-qPCR) 
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In order to perform accurate RT-qPCR measurements, an exhaustive selection of scientific literature 
available on MPM was carried out and a list of possible reference genes was gathered. The following 
data mining analysis by Coremine MedicalTM (http://www.coremine.com/medical/) revealed that most 
of these genes were involved in processes of development of several types of cancer, thereby raising 
doubts about their use as reference genes. Therefore, the mRNA expression levels of six genes, 
HPRT1, B2M, RPLP0, TBP, GUSB, and PPIA (genes known to be not involved in carcinogenesis), 
were measured in NMM and MPM tissues and cell lines and their stability was tested by geNorm [15]. 
Based on the average M and the pair-wise variation values, RPLP0, TBP, and HPRT1 were determined 
as the most stable and employed as reference genes for all the experiments.  
 
2.5 Primer design and RT-qPCR 
For each gene, primer pairs were designed in adjacent exons to allow specific amplification of mRNA 
instead of genomic DNA, by using Primer3 (http://frodo.wi.mit.edu/), “Primer-BLAST” 
(www.ncbi.nlm.nih.gov/tools/primer-blast), “Beacon Designer”, and “Netprimer” (PREMIER Biosoft; 
www.netprimer.com).  
Primer specificity was verified by running the PCR products on agarose gel electrophoresis and by 
analyzing the melting curves, to exclude the presence of primer dimers. To assess the efficiency of each 
primer pair, five serial dilutions were prepared from a pool of control cDNAs and used as template to 
generate the standard curves. Each RT-qPCR was set up in a final volume of 25 μl using 2 μl of cDNA, 
0.3 μM of forward and reverse primers and 5 μl of 5× Eva Green master mix with ROX as reference 
dye (Solis, Tartu, Estonia). The thermal cycling conditions were 15 min at 95°C followed by 15 s at 95 
°C, 30 s at 60 °C (40 cycles) and 30 s at 65 °C.  
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When the primer pair did not meet the required criteria of specificity or showed a low efficiency or 
reproducibility (thresholds: r2>0.96, 3.11<slope<3.58), pre-designed TaqMan probes (Life 
Technologies, Monza, Italy) were employed. For the TaqMan assay, the reaction mixture consisted of 2 
μl of cDNA template, 7 μl of deionized H2O, 1 μl of specific TaqMan Assay probe and primer mixture, 
and 10 μl of TaqMan® Gene Expression Master Mix (Life Technologies, Monza, Italy). The thermal 
cycling conditions were: 15 min at 95 °C followed by 15 s at 95 °C and 60 s at 60 °C (40 cycles). 
Primers and TaqMan ID assays are reported in Supplementary Table 1. Each sample was run in 
triplicate and the quality control of the derived expression values was performed according to MIQE 
guidelines [16]. When a sample did not meet any of the strict quality criteria for a given gene, the 
sample was not included in the statistical analysis for the considered gene. A gene was analyzed when 
the measurements of gene expression were available for a minimum of 75% of the samples, and all 
genes could be analyzed.   
 
2.6 Statistical analyses 
Gene expression levels from MPM samples were compared to NMM tissue samples by applying the 
one-tailed Wilcoxon test, in the Mann–Whitney version by R (www.r-project.org). The tested a priori 
hypothesis of up- or down-regulation for each gene was derived by Melaiu and colleagues paper [14]. 
For cell lines, two-tailed non parametric version of Dunnet-t test with Satterthwaite correction was 
adopted to compare gene expression levels of Mero-14 and Mero-25 with MeT-5A cell lines. The 
threshold of statistical significance for tissues and cell lines statistical analyses was fixed to 0.05 and 
multiple testing correction was performed by using Benjamini and Hochberg False Discovery Rate. 
The statistical analyses were performed by the R package.  
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WebGestalt (Gene Set Analysis Toolkit V2; http://bioinfo.van- derbilt.edu/webgestalt/) was employed 
to perform the overrepresentation analysis using the differentially expressed genes in tissues as input 
list. The whole human genome was selected as background.  
The OS was calculated from the diagnosis of malignancy until the patient death (also due to other 
causes), or until the last follow-up visit for still alive patients. The data were available for 13 patients 
who were censored at last follow-up visit if still alive or lost. Survival analysis was carried out using 
Kaplan–Meier curves and the significance was verified by a log-rank test. All P-values were 
determined by two-sided tests and corrected with Bonferroni’s adjustment in order to be considered 
statistically significant. Data analysis and summary graphs were produced by the software Statgraphics 
Centurion XV (StatPoint, Inc.). 
 
3. Results 
The expression levels of 119 candidate genes were measured in MPM and NMM tissues. The extent of 
differential expression was quantified by calculating the log2(fold change) (i.e. the log2(FC)), using 
NMM as control samples (see Table 2 for details). The table shows also information of the expected 
direction of deregulation (DOD), i.e. up- or down- regulation in MPM compared to normal pleura and 
represented as arrows, according to what summarized in RTS [14]. We found that 59 genes were 
differentially expressed (DE genes) between MPM and NMM in a statistically significant way, based 
on q-value: 51 were up-regulated and 8 down-regulated. All these DODs were comfortingly in 
agreement with the RTS. Forty-eight of the up-regulated genes showed a |log2(FC)| ≥1. In addition to 
the 59 DE genes, 25 showed a differential expression between MPM and NMM close to the statistical 
significance (q-value<0.10) and, for 22 of them, the DOD was in agreement with that reported in RTS. 
Among these 22, 12 had also a |log2(FC)| ≥1. Among the remaining 35 genes, 18 showed the DODs 
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expected from RTS although not reaching the statistical significance and 6 had also a |log2(FC)| ≥1. 
Thus, overall, 99 genes out of the 119 candidates (83%) showed DODs in agreement with previous 
findings from transcriptomic studies and 66 showed a |log2(FC)| ≥1.  
All the DE genes have been already studied in relation to various types of cancer in humans. Some of 
them, in particular BIRC5, CCNB1, CDC2, DSP, FEN1, ITGA4, MKI67, PCNA, PDGFRB, SMARCA4, 
TIMP3, and TOP2A count hundreds of citations in literature, whereas others such as ANK2, CXADR, 
C10orf116, GALNT7, FBLN2, HCA112, HEG1, TNPO2, and XPOT, have been reported only in few 
studies. Furthermore, MSLN, CALB2, BIRC5, PDGFRB, and MKI67 have been already described 
thoroughly in MPM and the present results reinforce the notion that they should have an important role 
in this disease. Concerning the remaining genes, very little is known, as most of them have never been 
studied either in MPM tissues or in cell lines. DE genes were also evaluated in relation to their possible 
belonging to specific pathways and 19 different KEGG-pathways were found overrepresented with 
statistical significance. The 5 most relevant pathways are reported in Table 3 and involve cell-cycle 
regulation, cell–cell and cell–matrix interactions, DNA replication, and cell energy metabolism. 
Finally, DE genes were also evaluated as potential prognostic biomarkers. Patients’ OS was inversely 
correlated with the expression of BIRC5, NME2, DSP, and THBS2 in a statistically significant way at 
nominal level of 0.05 (following the analysis of Kaplan-Meyer curves), but none of the genes resulted 
associated with OS after the correction for multiple tests. A brief analysis is reported in table 4, more 
details and Kaplan-Meyre curves are provided in supplementary data (Fig. S2).  
The 59 DE genes were further evaluated on Mero-14 and Mero-25 MPM cell lines (the non-MPM cell 
line Met-5A was adopted as reference). The expression levels of the candidate genes correlated in a 
statistically significant way when the two cell lines were compared to each other (r=0.84; slope=0.74; 
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std.error= 0.069; P-value<10-4; Fig. 2). When tissues were compared with cell lines, 28 genes showed, 
in at least one cell line, the same DOD found in tissues, and, in particular: 
• 9 genes (CCNO, CFB, PDGFRB, SULF1, THBS2, TIMP3, ACSL1, XPOT, TACC1) were deregulated 
with statistical significance in both the cell lines; 
• 12 genes (ASS1, COL1A1, CXADR, GALNT7, RAN, SOD1, EIF4G1, CCNB1, ITGA4, KRT5, CDH11, 
PTGIS) reached the statistical significance in one cell line only; 
• 7 genes (DSP, HEG1, MCM4, MSLN, NME2, TNPO2, NMU) showed a deregulation that did not 
reach the statistical significance in any of the cell lines.   
The remaining genes did not show DODs in agreement to those found in tissues.  
 
4. Discussion 
The screening of gene expression confirmed most of the findings described by RTS. However, none of 
the DE genes allowed distinguishing clearly MPM from NMM (Supplementary Fig. 2). Available 
evidences suggest that MPM is heterogeneous [2,17], and it is not an easy task to develop a simple 
diagnostic assay based on a single marker. Thus, here it is reinforced the notion that a panel of 
biomarkers will be needed to perform a correct diagnosis.  
In the present work genes involved in MPM were detected. They resulted positive to three stringent 
criteria: (i) deregulated in RTS, (ii) deregulated in MPM tissues, and (iii) deregulated in cell lines. It 
should be acknowledged that the cancer heterogeneity is so broad that two cell lines (such as Mero-14 
and Mero-25) might not be fully representative for MPM. However, it is conceivable that cell lines 
keep the original de-regulated status of (at least a share of) genes playing a crucial role in the disease, 
in spite of the changes occurred as a consequence of the adaptation to the in vitro growth conditions. 
Thus, the present work had the merit to highlight ACSL1, CCNO, CFB, PDGFRB, SULF1, THBS2, 
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TIMP3, XPOT, TACC1 as the strongest candidate cancer genes. However, also  ASS1, CCNB1,  
CDH11,  COL1A1, CXADR, DSP, EIF4G1, GALNT7, HEG1, ITGA4, KRT5, MCM4, MSLN, NME2, 
NMU, PTGIS, RAN, SOD1,   TNPO2 should be regarded as novel potential cancer genes worthy of 
further investigations. Among them, CDH11 (found up-regulated also in peritoneal mesothelioma [18], 
RAN (proposed as co-target for MPM treatment) [19], and THBS2 (whose antibody titer was proposed 
as tumor marker for the diagnosis and follow up of patients) [20], seem particularly interesting.  
Concerning cellular pathways, alterations in those devoted to the control of cell cycle and DNA 
replication are common hallmarks of cancer. Also alterations of metabolic pathways have been already 
correlated with human cancer [21-23]. Intriguingly, genes belonging to cell-cell and cell-matrix 
interactions were found deregulated in the present work. COL1A1 and TIMP3 (encoding for 
components of the matrix), ITGA4 (integrins), THBS2, and MSLN (surface glycoproteins) play 
fundamental roles in cell growth, survival, migration, epithelial-to-mesenchymal transition, and even 
metastasis [24-26]. It is suggested that a favorable tumor micro-environment is built also with the help 
of normal cells surrounding and or infiltrating the tumor. Future therapies for MPM could be aimed to 
interfere with these mechanisms.  
A further aim of the study was to evaluate how gene deregulation performs as prognostic biomarker. 
The actual number of analyzed patients was not appropriate for a thorough investigation. An altered 
expression of four genes (BIRC5, NME2, DSP, and THBS2) showed a correlation with patients’ OS 
only at nominal level of 0.05, that dropped after the adjustment for multiple tests. It could be 
hypothesized that higher expression of these genes were measured when biopsies have a low share of 
normal tissue. In other words, the expression of BIRC5, NME2, DSP, and THBS2 could be a proxy for 
the staging of the tumor. However, this is an unlikely explanation because OS would have been 
associated with a larger number of DE genes. Although, the study of OS could have been hampered by 
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a limited statistical power, the results are consistent with previous works carried out on MPM and on 
large series of other, less rare, tumors. In fact, a poor OS was significantly correlated with high 
expression of survivin mRNA in pleural effusions of patients diagnosed for MPM and lung 
adenocarcinoma [27], and in tumor tissues of patients diagnosed for colorectal [28], and breast cancer 
[29]. A poor OS was observed also among patients with high expression in tumor tissues of NME2 
(pancreatic, melanoma, hepatocellular, breast, ovarian, and gastric carcinoma patients [30-33], DSP 
(oral cancer patients) [34], and THBS2 (lung adenocarcinoma patients [35]. In summary, although 
MPM is a poorly studied cancer, some features are starting to emerge. Particularly, these findings 
provide some evidences on the role of genes involved in focal adhesion, metabolism and cell-matrix 
interaction. Further studies on the genes identified in the present work are needed to better ascertain 
their fruitful exploitation as therapeutic targets, or as diagnostic and prognostic biomarkers of MPM. 
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Figure Legends 
Figure 1. Fifty-one genes deregulated in a statistically significant way in MPM tissues were assayed in 
Mero-14 and Mero-25 MPM cell lines. The Fig. shows the correlation of the results obtained in the two 
cell lines. Gene expression level (as the logarithm base 2 of the fold change) and its statistical 
significance are calculated using the non-MPM cell line Met-5A as reference. The correspondence 
between labels and genes is reported in legend. Three genes, KRT5, CDH11, and PTGIS, showed an 
up-regulation in Mero-25 cells with a Log2(FC) of 1.685, 5.607, and 8.910 and P-values of 0.0198, 
<10-5, and <10-5, respectively but were undetectable in Mero-14 cells. The remaining genes 
(C10orf116, HCA112, SPINT2, UPK1B, FBLN2, ANK2, AOC3 and COL11A1) were undetectable in 
both cell lines. 
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LEGEND FIGURE 1:  
Mero 14-cells: ***for P-value≤10-5, **for P-values≤10-3, *for P-values≤0.05;  
Mero-25 cells: for P-value≤10-5, for P-values≤10-3, for P-values≤0.05. 
SULF1***; PDGFRB***; THBS2***; AKR1C1***; GALNT7***; CFB***; CXADR; COL1A1; RAN; SOD1; 
HEG1; TIMP3*; NME2; TNPO2; ITGA4***; 1=ASS1; 2=MCM4; 3=CCNO*; 4=XPOT***; 5=MSLN; 6=PCNA; 7=DSP; 
8=EIF4G1; 9=NMU; 10=PPARA; 11=CCNB1; 12=TACC1*; 13=PKM2; 14=GAPDH; 15=ALDOA; 16=KRT18*; 
17=HELLS***; 18=CENPF***; 19=SMC4***; 20=KIF23***; 21=ACSL1***; 22=NUSAP1***; 23=CHEK1***; 24=EFEMP1*; 
25=FEN1***; 26=MKI67***; 27=TOP2A***; 28=CCNB2***; 29=SMARCA4***; 30=BIRC5***;  31=CALB2***; 
32=CDC2***; 33=FANCI***  
 
Supplementary Figures 
Figure S1.  Kaplan-Meyer OS curves distinguishing MPM patients with intra-tumor gene expression 
levels over the median (dotted lines) from patients with gene expression levels below the median (solid 
lines). Only genes with expression levels showing a statistically significant difference at nominal level 
of 0.05 between the groups of patients are presented. None of the genes was associated in a statistically 
significant way with OS, following Bonferroni’s adjustment. Patients with the expression levels of the 
considered genes over the median showed poorer prognosis as compared to patients with gene 
expression levels below the median, with OSs of 20.8 months vs. 40 (P=0.016), 16.6 vs. 45 (P=0.016), 
15.6 vs. 43.6 (P=0.03), and 18.2 vs. 40.8 (P=0.05), for BIRC5, NME2, DSP, and THBS2, respectively. 
Figure S2.  
Box-and-Whisker-Plots of four deregulated genes showing the strongest statistical significance when 
comparing MPM and NMM tissues. 
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Table 1. Main characteristics of volunteers enrolled into the study; LA = Lung Adenocarcinoma; LSC 
= Lung Squamous Cell Carcinoma. 
Code SEX AGE MPM 
M01 F 40 Epithelioid 
M02 M 72 Biphasic 
M03 M 69 Epithelioid 
M04 M 56 Biphasic 
M05 M 86 Epithelioid 
M06 F 77 Epithelioid 
M07 M 69 Epithelioid 
M08 M 69 Epithelioid 
M09 M 87 Sarcomatoid 
M10 F 69 Sarcomatoid 
M11 M 87 Epithelioid 
M12 M 64 Epithelioid 
M13 F 60 Epithelioid 
M14 M 73 Epithelioid 
M15 M 68 Epithelioid 
M16 M 61 Epithelioid 
M17 M 48 Biphasic 
M18 M 64 Biphasic 
M19 M 64 Epithelioid 
M20 M 61 Epithelioid 
M21 M 65 Sarcomatoid 
M22 M 65 Epithelioid 
   NMM 
N01 M 74 LA 
N02 F 72 LSCC 
N03 M 85 LA 
N04 M 76 LA 
N05 M 77 LA 
N06 M 65 LSCC 
N07 F 65 LSCC 
N08 M 76 LSCC 
N09 M 80 LSCC 
N10 M 63 LSCC 
N11 F 69 LSCC 
N12 F 76 LSCC 
N13 F 69 LSCC 
N14 M 68 LSCC 
N15 M 68 LSCC 
N16 F 82 LSCC 
N17 M 76 LSCC 
N18 F 76 LSCC 
N19 F 59 LA 
N20 M 77 LA 
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Table 2. Statistical analyses testing differences in gene expression levels (expressed as logarithm base 
2 of the fold change) between MPM and NMM. Arrows show the direction of deregulation (DOD, ↑ 
up- or ↓ down-regulation) in MPM as compared to NMM, as expected from RTS. Results in 
disagreement are labeled with the symbol ↨; q-values= Benjamini and Hochberg False Discovery Rate. 
In bold are highlighted the 59 differentially expressed genes. 
 
Gene ID Log2(FC) q-value  Gene ID Log2(FC) q-value 
↑KIF23 1.879 1.70x10-4  ↑NMU 4.080 1.72X10-4 
↑CDH11 1.737 3.30X10-4  ↑MKI67 1.583 1.39X10-3 
↑COL1A1 4.680 2.40X10-3  ↑PTGIS 1.739 2.40X10-3 
↑CCNB2 3.411 2.40X10-3  ↑CCNB1 1.867 2.91X10-3 
↑TOP2A 3.073 3.24X10-3  ↑CHEK1 1.488 3.24X10-3 
↓ACSL1 -1.682 3.25X10-3  ↑HEG1 1.935 4.56X10-3 
↑PKM2 2.774 4.77X10-3  ↑FEN1 1.784 5.39X10-3 
↑CENPF 1.974 6.58X10-3  ↑FANCI 2.533 6.58X10-3 
↓FBLN2 -1.871 6.58X10-3  ↑SPINT2 4.642 8.99X10-3 
↑EIF4G1 1.601 8.99X10-3  ↑NUSAP1 1.460 9.83X10-3 
↓ANK2 -0.331 0.0103  ↑CALB2 5.670 0.0105 
↓AOC3 -1.316 0.0105  ↑GAPDH 0.946 0.0105 
↑SULF1 1.472 0.0151  ↑ASS1 2.282 0.0151 
↑MCM4 0.872 0.0163  ↑TIMP3 1.039 0.0163 
↑CCNO 3.172 0.0163  ↑KRT5 1.487 0.0163 
↑DSP 4.685 0.0163  ↑SMC4 0.914 0.0163 
↓C10orf116 -2.132 0.0188  ↑SMARCA4 0.606 0.0190 
↑TNPO2 3.803 0.0190  ↑GALNT7 2.276 0.0190 
↑MSLN 1.841 0.0221  ↑EFEMP1 0.931 0.0234 
↓TACC1 -0.650 0.0234  ↓PPARA -1.367 0.0235 
↑COL11A1 1.503 0.0247  ↑XPOT 0.334 0.0270 
↑HCA112 2.887 0.0276  ↑BIRC5 2.052 0.0276 
↑THBS2 4.985 0.0290  ↑CDC2 0.910 0.0314 
↑ITGA4 1.043 0.0331  ↓AKR1C1 -0.219 0.0354 
↑RAN 3.719 0.0354  ↑PDGFRB 2.791 0.0354 
↑NME2 1.939 0.0354  ↑CFB 1.054 0.0368 
↑SOD1 2.418 0.0373  ↑CXADR 3.512 0.0387 
↑UPK1B 5.202 0.0430  ↑PCNA 2.518 0.0430 
↑HELLS 1.237 0.0454  ↑KRT18 0.859 0.0479 
↑ALDOA 1.748 0.0479     
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↑THBS1 2.988 0.0552  ↑PLK2 0.810 0.0552 
↨BUB1B -0.103 0.0552  ↓EGR2 -0.782 0.0552 
↑SSBP1 2.605 0.0560  ↨COL6A1 0.850 0.0570 
↑EEF2 1.867 0.0601  ↑RAD21 4.809 0.0605 
↑CRIP1 1.455 0.0627  ↓EPAS1 -0.739 0.0695 
↑FGF9 2.935 0.0712  ↑VCAN 1.481 0.0716 
↓NR4A2 -0.333 0.0722  ↑VEGFA 2.138 0.0738 
↑S100A10 0.510 0.0761  ↑MCM2 0.820 0.0782 
↑PGM1 0.897 0.0788  ↑CCT2 0.710 0.0790 
↑LGALS3BP 1.891 0.0791  ↨CDK4 -1.036 0.0794 
↑PGK1 2.466 0.0847  ↑CDK7 0.428 0.0927 
↑CCNH 3.054 0.0953  ↓EGR3 -1.940 0.0953 
↓FBLN5 -0.412 0.0969     
       
↨FBLN1 0.341 0.110  ↑CDK2AP1 1.479 0.111 
↑RCN2 3.537 0.120  ↑EID1 0.526 0.120 
↨AURKA -0.233 0.123  ↓PECAM1 -0.335 0.126 
↓SFRP1 -0.482 0.126  ↑FAS 0.314 0.136 
↑PTGS2 0.134 0.162  ↑SYNE1 6.506 0.164 
↨IFITM1 -1.966 0.164  ↑NR3C1 1.083 0.172 
↑RHOB 0.277 0.172  ↨PDGFRA 0.003 0.178 
↑PSMD11 0.371 0.178  ↑DAP 0.027 0.187 
↑FGF2 1.611 0.257  ↓CAV1 -0.823 0.305 
↨CCND2 1.412 0.330  ↑SFRP2 1.337 0.363 
↨DAB2 -0.158 0.379  ↑FHL1 0.030 0.415 
↨IARS -0.631 0.422  ↨ANXA4 -0.362 0.422 
↨S100A11 -0.408 0.422  ↨CDKN1A 1.398 0.469 
↨METAP1 -0.361 0.470  ↨UBXN4 -0.256 0.476 
↨KIF5B -0.460 0.482  ↨TGFBR2 -0.247 0.482 
↨VWF 0.391 0.486  ↨IGFBP4 1.760 0.506 
↑ITGA6 0.016 0.511  ↨ASPA -1.544 0.511 
↑BLMH 0.092 0.511     
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Table 3. Five of the top 19 deregulated pathways detected by WebGestalt, based on the genes resulted 
deregulated in a statistically significant way. 
 
KEGG Pathway Genes mapped in the pathway 
Adjusted 
P-value 
Cell cycle MCM4, CHEK1, PCNA, CCNB1, CCNB2 1.23x10-5 
Focal adhesion COL11A1, THBS2, COL1A1, ITGA4, PDGFRB 4.29x10-5 
Extracellular Matrix-receptor interaction COL11A1, THBS2, COL1A1, ITGA4 4.29x10-5 
DNA replication MCM4, PCNA, FEN1 7.20x10-5 
Metabolic pathways ASS1, AOC3, GALNT7, GAPDH, ACSL1, PTGIS, ALDOA, NME2 8.77x10-4 
 
 
 
 
Table 4. Data showing the expression of specific genes in relation to the censored status. None of the 
genes analysed with Kaplan-Meyer (see supplementary data, Fig. S1) reached the statistical 
significance after Bonferroni’s correction. L= gene expression below the median, H= gene expression 
over the median, N/A= sample excluded following quality control. 
 
 BIRC5 DSP NME2 THBS2 
Status (Censored) L H N/A L H N/A L H N/A L H N/A 
Alive 5 1 0 3 1 2 3 1 2 2 1 3 
Deceased 0 4 3 2 4 1 3 4 0 3 4 0 
% of deceased patients 0 80  40 80  50 80  60 80  
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Fig. 1. Fifty-one genes deregulated in a statistically significant way in MPM tissues were assayed in 
Mero-14 and Mero-25 MPM cell lines. The figure shows the correlation of the results obtained in the 
two cell lines. Gene expression level (as the logarithm base 2 of the fold change) and its statistical 
significance are calculated using the non-MPM cell line Met-5A as reference. The correspondence 
between labels and genes is reported in legend. Three genes, KRT5, CDH11, and PTGIS, showed an 
up-regulation in Mero-25 cells with a Log2(FC) of 1.685, 5.607, and 8.910 and P values of 0.0198, 
<10−5, and <10−5, respectively but were undetectable in Mero-14 cells. The remaining genes 
(C10orf116, HCA112, SPINT2, UPK1B, FBLN2, ANK2, AOC3 and COL11A1) were undetectable in 
both cell lines. Mero 14-cells: ***for P value ≤10−5, **for P values ≤10−3, *for P values ≤0.05; Mero-
25 cells: †††for P value ≤10−5, ††for P values ≤10−3, †for P values ≤0.05. SULF1***†††; 
PDGFRB***†††; THBS2***†††; AKR1C1***†††; GALNT7***; CFB***††; CXADR†††; 
COL1A1†††; RAN†; SOD1†; HEG1; TIMP3*†††; NME2; TNPO2; ITGA4***; 1 = ASS1†††; 2 = 
MCM4; 3 = CCNO*†††; 4 = XPOT***††; 5 = MSLN; 6 = PCNA; 7 = DSP; 8 = EIF4G1†††; 9 = 
NMU; 10 = PPARA; 11 = CCNB1†; 12 = TACC1*†; 13 = PKM2; 14 = GAPDH†††; 15 = ALDOA; 
16 = KRT18*; 17 = HELLS***; 18 = CENPF***†; 19 = SMC4***; 20 = KIF23***; 21 = 
ACSL1***†; 22 = NUSAP1***; 23 = CHEK1***; 24 = EFEMP1*†††; 25 = FEN1***; 26 = 
MKI67***†††; 27 = TOP2A***†††; 28 = CCNB2***†; 29 = SMARCA4***†††; 30 = BIRC5***†††; 
31 = CALB2***; 32 = CDC2***†††; 33 = 
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FANCI***†††
 
